-
May 17, 2013
This time the firm has been hit for ‘disparaging comparisons’ between its Gaucher's disease drug Vpriv and Genzyme’s rival treatment in a press release
-
May 17, 2013
Betmiga gets final draft yes from the Institute as Astellas looks to replace its ageing OAB drug Vesicare
-
May 16, 2013
NHS England and health sector regulator Monitor have opened a consultation on proposals to reform the way NHS services are paid for.NHS England
-
May 16, 2013
The UK Government wants to see the 160,000 people who are unknowingly living with the condition identified and treated
-
May 16, 2013
NICE will produce a stream of medical technology innovation briefings designed to boost their adoption throughout the health service.
-
May 15, 2013
Generic forms of Pfizer’s once blockbuster comes with a price tag 85% lower than its patented equivalent, helping make significant savings for the NHS
-
May 15, 2013
Dr Jean-Michel Cosséry would like to see a more refined and detailed discourse on opening up clinical trial data
-
May 14, 2013
The National Institute for Health and Clinical Excellence has been asked by the government to develop quality standards (QS) in public health, adding to its existing programme of work within health and social care.
-
May 14, 2013
Medication needs to move back to positivity, and the challenge of achieving this represents huge opportunities for the pharmaceutical industry, a recent meeting of the PharmaTimes Directors Club (PDC) has heard.
-
May 14, 2013
SMC green light for Shire's ADHD drug Elvanse, Novartis eye drug Lucentis and Astellas Betmiga for overactive bladder, but it's a no for Pfizer personalised NSCLC drug Xalkori.